Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Filgotinib Mini-tablet Formulation
NCT06043739Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC) (3 arms), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration of filgotinib, Maximum observed plasma concentration of GS-829845 (major active metabolite) and 4 more. Started Sep 2023; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06043739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043739.